{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 311,
  "pageCount": 415,
  "prevPage": 310,
  "nextPage": 312,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses a Q&A format to document expert testimony regarding trial integrity.",
  "elementsJson": [
    "paragraph",
    "quote_block",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/311",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-311",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Trial was essentially unblinded from side effects; investigators correctly deduced who was on drug vs. placebo",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b0-951bb62a75ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.79
      },
      "kind": "list",
      "text": "Q&A transcript regarding the ability to deduce drug assignment via side effects like peripheral edema.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e1b8493-bbf3-4292-a459-5c7b51df2fe6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.71
      },
      "kind": "paragraph",
      "text": "Trial was essentially unblinded from side effects; investigators correctly deduced who was on drug vs. placebo",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "44ec0596-5c46-4d80-b927-5d8ae17b08e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.86,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "HQ-CT endpoint had “tons of problems”; lack of weight loss with Vykat is troubling",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd6b3dad-f4c1-483a-843d-a94036554186",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.86,
        "x": 0.07,
        "y": 0.55
      },
      "kind": "quote",
      "text": "“And to then not have a harder endpoint...there’s tons of problems with that score...I would have expected that if hyperphagia went down, we would see...weight went down as well. And we didn’t see that in this study.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "062965cc-8e28-4910-9a79-c491c64c348d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.86,
        "x": 0.07,
        "y": 0.74
      },
      "kind": "quote",
      "text": "“The hypertrichosis is likely to unblind people and peripheral edema will. Yes, I think there is a real risk of functional unblinding, for sure.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a786a076-a2d1-426a-96ae-55545a681567",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“And to then not have a harder endpoint. With a reduction in hyperphagia, that as an outcome is not really measurable...there's tons of problems with that score...I would have expected that if hyperphagia went down, we would see, as in the beloranib study...weight went down as well. And we didn't see that in this study. I'm not quite sure what's going on there.” — Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2b0-9bd916c021aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77c97224-228d-436a-9a0a-0284e29af139",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #4 was highly skeptical of Soleno’s trials and overall conduct, stating that the subjective HQ-CT hyperphagia questionnaire had “tons of problems” and that the lack of weight loss was troubling given the purported hyperphagia reduction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5651289-39a6-469a-b8ce-c94ec87c6294",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "99a722aa-a43c-4417-875d-d92971b8d70c",
      "evidence": "The slide explicitly frames trial results as unreliable due to endpoint flaws and unblinding.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}